The anti-diabetic effect of cytogenin was examined using streptozotocin-induced diabetes in mice. Cytogenin suppressed not only the increase of plasma glucose level but also the body weight reduction in diabetic mice. Histological examination of the pancreas taken from diabetic mice given cytogenin showed that cytogenin decreased the number of macrophages infiltrated into islet of pancreas. Further, cytogenin suppressed the nitric oxide generation by macrophages treated with lipopolysaccharide through decreasing of inducible nitric oxide synthase expression. Cytogenin suppressed interleukin-6 expression by macrophage treated with LPS, suggesting that the antidiabetic activity of cytogenin might be partly attributed to the suppressive activity against nitric oxide generation.
diabetic activity on streptozotocin (STZ)-induced diabetes in mice, which is thought to be an experimental model of insulin dependent diabetes mellitus (IDDM).
Diabetes was induced by STZ according to the methods reported by Nakamura et al. [7] . Briefly, ICR mice (7 weeks old, male) were given i.p. at 40 mg/kg of STZ for 5 successive days. Cytogenin at 10, 30 and 100 mg/kg/day was given p.o. for 18 days from the first injection of STZ. Mice (8 to 10 mice/experimental group) were housed and kept under a specific pathogen-free condition. Twice a week after STZ treatment, the body weight change of mice was measured. The induction of diabetes in mice treated with STZ was determined by glucose level of plasma and infiltration of macrophages around the islet of pancreas by histrogical examinations. Twice a week after STZ treatment, the glucose level in plasma of each mouse was determined by the glucose oxidase method (Glucose B test Wako, Wako Chemical Co., Japan). On day 32 after STZ treatment, the pancreas of each mouse was extirpated, fixed with 10% buffered formalin and then embedded in paraffin. The infiltration of macrophages into islets of Langerhans was determined microscopically with the hematoxylineosin stained sections. The degree of infiltration was scored as follows: grade 0, no infiltration; grade 1, slight infiltration; grade 2, moderate infiltration; grade 3, severe infiltration. Scores were calculated statistically using the Mann Whitney's U-test.
We examined the effect of cytogenin on inflammatory factors related to diabetes development such as nitric oxide (NOx), IL-1 and IL-6 produced by macrophages. CDF1 mice (7 weeks old, female, 5 mice/experimental group) were given i.p. at 50 mg/kg of Zymosan. From the next day, cytogenin was given p.o. for 10 successive days at 100 mg/kg. On day 12 after Zymosan treatment, peritoneal macrophages were collected and cultured with 0.5 mg/ml of LPS for 24 hours at 1ϫ10 6 cells/ml in RPMI-1640 medium supplemented with 10% FCS. The culture supernatant was collected and the concentration of NOx was measured by the method reported by Keller et al. [8] . Briefly, 100 ml of Griess reagent was mixed with 100 m l of the culture supernatant and incubated for 10 minutes at room temperature. The absorbance at 540 nm of the mixture was measured by a plate reader. NOx concentration was calculated from a NaNO 2 standard curve. Inducible nitric oxide synthase (iNOS) in macrophages was detected by Western blotting. The macrophages cultured as mentioned above were lysed with a lysis buffer. Equal protein extracts were separated by SDS-PAGE and transferred onto PVDF membrane. Enhanced chemiluminescence was used to visualize the immunoblot signals of iNOS. Quantification of iNOS protein was performed by using the NIH image software.
CDF1 mice (7 weeks old, female, 5 mice/experimental group) were given p.o. at 100 mg/kg of cytogenin for 10 successive days. On day 11 after start of the administration, peritoneal macrophages were collected and cultured at 1ϫ10 6 cells/ml for 24 hours with 0.5 m g/ml of LPS. Concentrations of IL-1 and -6 in the culture supernatant were measured with a commercial ELISA kit, respectively.
The body weight of mice was monitored in each experimental group. Treatment with STZ suppressed the normal increase of body weight of mice in comparison with non-treated mice. The suppression of body weight caused by STZ was inhibited by the administration of cytogenin at 30 and 100 mg/kg but not at 10 mg/kg (Fig. 1a) .
The glucose level in plasma of mice treated with STZ was measured as an indicator for diabetes. Treatment with STZ increased the glucose level in plasma from day 12 through day 32 gradually. This increase in glucose level caused by STZ was significantly suppressed by cytogenin at 30 and 100 mg/kg (Fig. 1b) . The glucose concentration on day 32 in each group was as follows: 174Ϯ6 in non-treated mice, 542Ϯ68 mg/dl in mice treated with STZ alone, 532Ϯ51 mg/dl in mice given 10 mg/kg of cytogenin with STZ, 332Ϯ76 mg/dl in mice given 30 mg/kg of cytogenin with STZ, 312Ϯ64 mg/dl in mice given 100 mg/kg of cytogenin with STZ.
The infiltration of macrophages into islets of pancreas was examined (Fig. 2 ) and recorded as a score. As shown in Fig. 3 , the scores in pancreas of mice given 30 and 100 mg/kg of cytogenin were significantly lower than that of mice treated with STZ alone (Fig. 3) .
The NOx production of macrophages in culture was enhanced by elicitation with Zymosan and LPS-treatment from 2 nmol/10 6 to 40 nmol/10 6 cells. This increase in NOx production was significantly suppressed by cytogenin to 24 nmol/10 6 cells (Fig. 4a) . The production of iNOS in the macrophages was also suppressed by cytogenin (Fig. 4b) .
The IL-6 production of macrophages in culture was enhanced by LPS-treatment from 3 ng/ml to 42 ng/ml. This increase in IL-6 production by the macrophages was significantly suppressed by cytogenin from 42 ng/ml to 17 ng/ml (Fig. 5) . On the other hand, the IL-1 production by the macrophages in culture with LPS was not affected by cytogenin (data not shown).
STZ treated mice [7] and spontaneous onset mice [9, 10] have been developed for analyzing the onset mechanism of IDDM. The mechanism of diabetes development is still unclear, although STZ is known to induce autoimmunity to Langerhans' islet. It has been reported that NOx may mediate immunologically induced b -cell dysfunction in type I diabetes [11ϳ13] . It is well known that NOx is generated by iNOS, which is produced by macrophages and b -cells in the pancreas, and the production of iNOS is stimulated by some inflammatory cytokines, such as IL-1, IL-6, TNF-a and IFN-g [14, 15] . In this context, we found that cytogenin suppressed not only NOx production but also iNOS and IL-6 expressions of LPS-treated macrophages in culture. The anti-diabetic action of cytogenin might be attributed by the suppression of NOx activity through modulation of activities of some inflammatory cytokines.
Although cytogenin suppressed the infiltration of macrophages into islet of pancreas dose dependently, plasma glucose level at 100 mg/kg was not normalized. Since cytogenin did not suppress the infiltration of macrophages completely in the score, cytogenin might not normalize the glucose level at the highest dose. The mechanism of the suppression of macrophage infiltration into islet is not clear. Cytogenin may also suppress the secretion of some chemokines such as IL-8 having chemotactic activity.
Since cytogenin is a compound with low toxicity and high bioavailability in experimental animals, it is a valuable lead compound in developing treatment of human type I diabetes.
